The objective of this research programme is to reduce the time between the discovery of new targets and drug candidates in the field of neurological diseases and their therapeutic application in adults and child. The main goal is to overcome the difficulties encountered by academic research in the transition from the laboratory to the patient, and thus to accelerate the development of therapies.
A battery of tests, in vitro, in vivo, on a wide range of animal models (genetic and pharmacological and neurotoxic) and finally in humans, are implemented by NeurATRIS to perform preclinical and clinical research allowing academic and/or industrial researchers to revalidate identified targets (preclinical PoC) and to access phase I/II clinical trials (clinical PoC, first in man). NeurATRIS has a large range of in vitro and in vivo models/tools capable of identifying and validating the targets of proposed new therapeutic strategies as well as large cohorts of patients affected by the main neurological diseases of adults and children.
NeurATRIS is home to numerous translational approaches for the development of effective drug strategies not only against various adult diseases but also against two major diseases of the developing brain, cerebral palsy and epilepsy. This area of research remains largely unexplored, particularly because of the specificities of immature brain models and the ethical difficulties of trials involving neonates and children. Pre-clinical testing for children's medicines is nevertheless a mandatory step, in accordance with European legislation (European Paediatric Regulation) which, since 2007, requires non-clinical testing on young animals for adult medicines with paediatric indications.
Inhibiting misfolded protein propagation in neurodegenerative diseases Acronym : IMPRIND Coordinator : G. TOFARIS Partners : 18 participants in 7 countries, including CEA/MIRCen (France) Funding : European Commission, Innovative Medicines Initiative Project duration : 2017-2022
A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease Acronym : PD-MitoQUANT Coordinator : J. PREHN (Dublin, Irlande) Partners : 14 participants in 9 countries including CEA/MIRCen and ICM - Pitié Salpêtrière Hospital Funding : European Commission, Innovative Medicines Initiative Project duration : 2019-2022
Development of kallikrein-related peptidase 6 inhibitors to treat MS Acronym : RESTORE Partners : ICM – Pitié Salpêtrière Hospital Funding : ANR PRC Project duration : 48 months
Calcitonin receptor (CGRP): A New Therapeutic Target to Promote Remyelination in Multiple Sclerosis Partners : ICM – Pitié Salpêtrière Hospital Funding : ARSEP Project duration : 12 months
Modulation of microglia-node of Ranvier interaction by neuronal activity and inflammatory cues – Impact on remyelination Partners : ICM – Hôpital Pitié Salpêtrière Funding : ARSEP Project duration : 12 months
Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis Acronym : BRAVEinMS Partners : ICM – Hôpital Pitié Salpêtrière, Consortium BRAVEinMS Funding : Progressive MS Alliance - NMSS Project duration : 2017-2022
Microglia and Remyelination; Does electrical activity regulate the pro-remyelinating effect of microglial cells? Partners : ICM – Pitié Salpêtrière Hospital Funding : Progressive MS Alliance - NMSS Project duration : 2021-2022
OPC-driven Angiogenesis and its modulation by Neuronal Activity Acronym : ODANA Partners : ICM – Pitié Salpêtrière Hospital - Big Brain Theory Funding : ICM – Pitié Salpêtrière Hospital Project duration : 2022-2023